CG Oncology, Inc. (CGON) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US1569441009
CG Oncology, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 4.04 m USD |
| Operating income | -190.77 m USD |
| EBIT | -191.20 m USD |
| Net income | -161.00 m USD |
| Diluted EPS – continuing operations | -2.08 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CG Oncology, Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
More stocks
- ACI WORLDWIDE, INC. (ACIW)
- Ollie's Bargain Outlet Holdings, Inc. (OLLI)
- Zhongce Rubber Group Co Ltd (603049.SS)
- Octave Intelligence plc (OCTV)
- ASSOCIATED BANC-CORP (ASB)
- OUTFRONT Media Inc. (OUT)
- Glarun Technology Co Ltd (600562.SS)
- JBT MAREL Corp (JBTM)
- Tokyu Fudosan Holdings Corp (3289.T)
- RadNet, Inc. (RDNT)
- Joinn Laboratories(China)Co (603127.SS)
- Logista Integral SA (LOG.MC)
Not investment advice. All data without warranty, price as of 20.10.2026. Details in the risk notice.